Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study

October 11, 2023 updated by: Zhe Fan
The goal of this observational study is to learn about in small bowel adenocarcinoma patients. The main question it aims to answer is the association between tumor size and prognosis in patients with small bowel adenocarcinoma. Participants will be compared for the relationship between tumor size and prognosis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

8163

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Liaoning
      • Dalian, Liaoning, China
        • Dalian Third People's Hospital Affiliated to Dalian Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Data of Small Bowel adenocarcinoma patients from 2004 to 2019 was collected from the SEER database using the SEER*Stat software (version 8.4.0.1).

Description

Inclusion Criteria:

  1. pathology confirmed as SBA;
  2. received surgery and complete postoperative follow-up data;
  3. histology type code 8140-8380.

Exclusion Criteria:

Cases with unknown tumor location, size, TNM staging, race, and degree of differentiation were excluded. Finally, 8,163 eligible patients were included in the analysis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
tumor size 0-1cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 0-1 cm.
Other: no interventions
no interventions
tumor size 1-2 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 1-2 cm.
tumor size 2-3 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 2-3 cm.
tumor size 3-4 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 3-4 cm.
tumor size 4-5 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 4-5 cm.
tumor size 5-6 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 5-6 cm.
tumor size 6-7 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 6-7 cm.
tumor size 7-8 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 7-8 cm.
tumor size 8-9 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 8-9 cm.
tumor size 9-10 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of 9-10 cm.
tumor size >10 cm
No intervention. Select small bowel adenocarcinoma patients with tumor size of >10 cm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study
Time Frame: 2024.9.1
We will study the relationship between tumor size and prognosis in small bowel adenocarcinoma patients in the SEER database
2024.9.1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhe Fan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Actual)

September 1, 2023

Study Completion (Actual)

October 1, 2023

Study Registration Dates

First Submitted

October 11, 2023

First Submitted That Met QC Criteria

October 11, 2023

First Posted (Actual)

October 18, 2023

Study Record Updates

Last Update Posted (Actual)

October 18, 2023

Last Update Submitted That Met QC Criteria

October 11, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ThirdPHDalian

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prognosis

Clinical Trials on no interventions

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe